Pharmacokinetics of lopinavir after administration of Kaletra in healthy Japanese volunteers

Biological and Pharmaceutical Bulletin

Volumn 27, Issue 2, 2004, Pages 261-265

  Oki, Tsuyoshi ^a   Usami, Yoshiko ^a   Nakai, Masahiko ^a   Sagisaka, Masafumi ^a   Ito, Hirotaka ^a   Nagaoka, Koichi ^a   Mamiya, Naoto ^a   Yamanaka, Katsuo ^a   Utsumi, Makoto ^a   Kaneda, Tsuguhiro ^a  

^a NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

Author keywords

Fasting study; Human immunodeficiency virus (HIV) 1; Lopinavir; Pharmacokinetics; Postprandial study; Ritonavir

Indexed keywords

LOPINAVIR; LOPINAVIR PLUS RITONAVIR; RITONAVIR; PROTEINASE INHIBITOR; PYRIMIDINONE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CALCULATION; DIET RESTRICTION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; FOOD INTAKE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; POSTPRANDIAL STATE; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; FOOD DRUG INTERACTION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TIME;

ADMINISTRATION, ORAL; ADULT; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; POSTPRANDIAL PERIOD; PROTEASE INHIBITORS; PYRIMIDINONES; RITONAVIR; TIME FACTORS;

EID: 16544370517     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.27.261     Document Type: Article

References (12)

1. Sham H. L., Kempf D. J., Molla A., Marsh K. C., Kumar G. N., Chen C. M., Kati W., Stewart K., Lal R., Hsu A., Betebenner D., Korneyeva M., Vasavanonda S., McDonald E., Saldivar A., Wideburg N., Chen X., Niu P., Park C., Jayanti V., Grabowski B., Granneman G. R., Sun E., Japour A. J., Leonard J. M., Plattner J. J., Norbeck D. W., Antimicrob. Agents Chemother., 42, 3218-3224 (1998).
2. Kumar G. N., Jayanti V., Lee R. D., Whittern D. N., Uchic J., Thomas S., Johnson P., Grabowski B., Sham H., Betebenner D., Kempf D. J., Denissen J. F., Drug Metab. Dispos., 27, 86-91 (1999).
3. Kumar G. N., Dykstra J., Roberts E. M., Jayanti V. K., Hickman D., Uchic J., Yao Y., Surber B., Thomas S., Granneman G. R., Drug Metab. Dispos., 27, 902-908 (1999).
4. Corbett A. H., Lim M. L., Kashuba A. D. M., Ann. Pharmacother., 36, 1193-1203 (2002).
5. Product information (in Japanese), Kaletra (lopinavir/ritonavir), Abbott Park, IL: Abbott Laboratories, 2000.
6. Bertz R., Lam W., Hsu A., Granneman G. R., Sun E., 2nd International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, The Netherlands, on 2-4 April 2001.
7. Usami Y., Oki T., Nakai M., Sagisaka M., Kaneda T., Chem. Pharm. Bull., 51, 715-718 (2003).
8. Yamaoka K., Tanigawara Y., Nakagawa T., Uno T., J. Pharmacobio-Dyn., 4, 879-885 (1981).
9. Akaike H., IEEE Trans. Automat. Contr., 19, 716-723 (1974).
10. Gustavson L., Lam W., Bertz R., Hsu A., Rynkiewicz K., Qi J., Ghosh S., Facey I., Bernstein B., Sun E., 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, on 17-20 September 2000.
11. Bertz R., Renz C., Foit C., Swerdlow J., Ye X., Jasinsky O., Hsu A., Granneman G. R., Sun E., 2nd International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, The Netherlands, on 2-4 April 2001.
12. Fellay J., Marzolini C., Meaden E. R., Back D. J., Buclin T., Chave J.-P., Decosterd L. A., Furrer H., Opravil M., Pantaleo G., Retelska D., Ruiz L., Schinkel A. H., Vernazza P., Eap C. B., Telenti A., Lancet, 359, 30-36 (2002).